2nd Quarter - Report

BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) for BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

Firm
Client
Income
—
Expenses
$480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]

LobbyistCovered position, as disclosed
DIANA CHRISTIAN New —
EMILY SHETTY Legislative Director, Rep. Edolphus Towns

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 2607 (113th), H.R. 1801 (113th), H.R. 460 (113th), H.R. 2019 (113th), H.R. 1239 (113th)

Budget/Appropriations BUD

Issues pertaining to the FDA drug approval process and agency funding - [FY14 Agriculture, Rural Development, Food and Drug Administration and Related Agencies subcommittee bill]; Issues pertaining to funding for the National Center for the Advancement of Translational Sciences and the National Institutes of Health, specifically pediatric and general cancer research- [FY14 Labor Health and Human Services and Related Agencies subcommittee bill- provisions related to NCATS & NIH]

LobbyistCovered position, as disclosed
DIANA CHRISTIAN New —
EMILY SHETTY Legislative Director, Rep. Edolphus Towns

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.